ArticleFuture oncology (London, England)2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in Italy.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedCorrection.2026
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the differences in clinical outcomes and costs for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) with a combined positive score (CPS) of 1-19, with pembrolizumab ± chemotherapy or a cetuximab-containing regimen (CCR) in Italy.
methodsA naïve indirect treatment comparison was conducted, and outcomes were incorporated into a newly developed cost-utility model. Inputs were derived from clinical trials, technology appraisal reports, and published literature. Scenario analyses were undertaken to explore key areas of uncertainty.
resultsAcross the comparisons of pembrolizumab ± chemotherapy versus CCRs, incremental life-years ranged from - 0.502 to 0.155, while incremental quality-adjusted life years (QALYs) ranged from - 0.379 to 0.085. In some scenarios, CCRs dominated pembrolizumab ± chemotherapy (i.e. more QALYs at lower costs). In others, CCRs yielded similar estimates of QALYs at lower costs.
conclusionCCRs are likely to represent a comparable or more effective treatment option compared to pembrolizumab ± chemotherapy. Model results consistently demonstrated that CCRs are a cost-effective treatment strategy. CCRs remain a relevant treatment option for R/M SCCHN and a CPS of 1-19, for whom a targeted, patient-focused approach is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.